Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease

Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes. The aim of this study was to evaluate the effect of melatonin (MEL) on the PER1 and BMAL1 clock genes in patient...

Full description

Bibliographic Details
Main Authors:	D.L. Delgado-Lara, G.V. González-Enríquez, B.M. Torres-Mendoza, H. González-Usigli, J. Cárdenas-Bedoya, M.A. Macías-Islas, A. Celis de la Rosa, A. Jiménez-Delgado, F. Pacheco-Moisés, J.A. Cruz-Serrano, G.G. Ortiz
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Melatonin Clock genes BMAL1gene PER1gene Parkinson's disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332220306788

id	doaj-abb7d0457c2449cdb7a5370acdda57f9
record_format	Article
spelling	doaj-abb7d0457c2449cdb7a5370acdda57f92021-05-20T07:42:58ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-09-01129110485Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s diseaseD.L. Delgado-Lara0G.V. González-Enríquez1B.M. Torres-Mendoza2H. González-Usigli3J. Cárdenas-Bedoya4M.A. Macías-Islas5A. Celis de la Rosa6A. Jiménez-Delgado7F. Pacheco-Moisés8J.A. Cruz-Serrano9G.G. Ortiz10Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico; Division of Neurosciences, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Jalisco, MexicoDepartment of Neurology, Sub-Specialty Medical Unit, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, MexicoDepartment of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Neurosciences, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Public Health, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Chemistry, University Center of Exact Sciences and Engineering, University of Guadalajara, Guadalajara, Jalisco, MexicoDepartment of Chemistry, University Center of Exact Sciences and Engineering, University of Guadalajara, Guadalajara, Jalisco, MexicoKurago Biotek, Guadalajara, Jalisco, MexicoDepartment of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico; Department of Neurology, Sub-Specialty Medical Unit, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico; Corresponding author at: Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Sierra Mojada N/N, PC 14340. Col. Independencia, Guadalajara, Jalisco, Mexico.Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes. The aim of this study was to evaluate the effect of melatonin (MEL) on the PER1 and BMAL1 clock genes in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial pilot study was conducted in 26 patients with stage 1–3 PD according to the Hoehn & Yahr scale, who received either 25 mg of MEL or a placebo at noon and 30 min before bedtime for three months. The relative expression of the PER1 and BMAL1 genes was measured, as well as the presence of daytime, nocturnal, and global sleepiness, and the progression of PD. The levels of the PER1 and BMAL1 genes at baseline were 0.9 (0.1–3) vs. 0.56 (0.1−2.5), respectively; while after the intervention with MEL or placebo the BMAL1 levels increased to 2.5 (0−3.70) vs. 2.2 (0.10–3.30), respectively (d = 0.387). Fifty percent (50 %) of patients had daytime sleepiness and sixty-five percent (65 %) had abnormal nighttime sleepiness, yet neither group showed changes after the intervention. Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.http://www.sciencedirect.com/science/article/pii/S0753332220306788MelatoninClock genesBMAL1genePER1geneParkinson's disease
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	D.L. Delgado-Lara G.V. González-Enríquez B.M. Torres-Mendoza H. González-Usigli J. Cárdenas-Bedoya M.A. Macías-Islas A. Celis de la Rosa A. Jiménez-Delgado F. Pacheco-Moisés J.A. Cruz-Serrano G.G. Ortiz
spellingShingle	D.L. Delgado-Lara G.V. González-Enríquez B.M. Torres-Mendoza H. González-Usigli J. Cárdenas-Bedoya M.A. Macías-Islas A. Celis de la Rosa A. Jiménez-Delgado F. Pacheco-Moisés J.A. Cruz-Serrano G.G. Ortiz Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease Biomedicine & Pharmacotherapy Melatonin Clock genes BMAL1gene PER1gene Parkinson's disease
author_facet	D.L. Delgado-Lara G.V. González-Enríquez B.M. Torres-Mendoza H. González-Usigli J. Cárdenas-Bedoya M.A. Macías-Islas A. Celis de la Rosa A. Jiménez-Delgado F. Pacheco-Moisés J.A. Cruz-Serrano G.G. Ortiz
author_sort	D.L. Delgado-Lara
title	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease
title_short	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease
title_full	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease
title_fullStr	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease
title_full_unstemmed	Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease
title_sort	effect of melatonin administration on the per1 and bmal1 clock genes in patients with parkinson’s disease
publisher	Elsevier
series	Biomedicine & Pharmacotherapy
issn	0753-3322
publishDate	2020-09-01
description	Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes. The aim of this study was to evaluate the effect of melatonin (MEL) on the PER1 and BMAL1 clock genes in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial pilot study was conducted in 26 patients with stage 1–3 PD according to the Hoehn & Yahr scale, who received either 25 mg of MEL or a placebo at noon and 30 min before bedtime for three months. The relative expression of the PER1 and BMAL1 genes was measured, as well as the presence of daytime, nocturnal, and global sleepiness, and the progression of PD. The levels of the PER1 and BMAL1 genes at baseline were 0.9 (0.1–3) vs. 0.56 (0.1−2.5), respectively; while after the intervention with MEL or placebo the BMAL1 levels increased to 2.5 (0−3.70) vs. 2.2 (0.10–3.30), respectively (d = 0.387). Fifty percent (50 %) of patients had daytime sleepiness and sixty-five percent (65 %) had abnormal nighttime sleepiness, yet neither group showed changes after the intervention. Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.
topic	Melatonin Clock genes BMAL1gene PER1gene Parkinson's disease
url	http://www.sciencedirect.com/science/article/pii/S0753332220306788
work_keys_str_mv	AT dldelgadolara effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT gvgonzalezenriquez effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT bmtorresmendoza effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT hgonzalezusigli effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT jcardenasbedoya effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT mamaciasislas effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT acelisdelarosa effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT ajimenezdelgado effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT fpachecomoises effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT jacruzserrano effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease AT ggortiz effectofmelatoninadministrationontheper1andbmal1clockgenesinpatientswithparkinsonsdisease
_version_	1721434915235430400

Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson’s disease

Similar Items